OTCMKTS:SHTDY Sinopharm Group (SHTDY) Stock Price, News & Analysis $9.95 +0.07 (+0.75%) As of 10:53 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividend About Sinopharm Group Stock (OTCMKTS:SHTDY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sinopharm Group alerts:Sign Up Key Stats Today's Range$9.95▼$10.1150-Day Range$9.33▼$10.9852-Week Range$9.00▼$14.87Volume7,870 shsAverage Volume106,498 shsMarket CapitalizationN/AP/E Ratio1.99Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Sinopharm Group Co., Ltd. is a China-based pharmaceutical and healthcare company and a core subsidiary of China National Pharmaceutical Group Corporation (Sinopharm). Established in 2003, the company operates primarily across mainland China and serves hospitals, pharmacies, medical institutions and other healthcare customers. The company’s principal business is pharmaceutical distribution, covering prescription medicines, over-the-counter products, traditional Chinese medicines, vaccines and other healthcare products. Sinopharm Group also distributes medical devices and equipment, providing procurement, logistics, warehousing and supply-chain services to healthcare providers and manufacturers. In addition to distribution, Sinopharm Group has operations in pharmaceutical retail, pharmaceutical manufacturing and healthcare-related services. Its manufacturing activities include medicines and other healthcare products, while its retail business serves consumers through pharmacy operations. The company’s shares are listed in Hong Kong, and its American depositary shares trade over the counter in the United States under the symbol SHTDY.AI Generated. May Contain Errors. Read More Receive SHTDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sinopharm Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SHTDY Stock News HeadlinesSinopharm Group Co. Ltd. (OTCMKTS:SHTDY) Shares Shorted: Short Interest Up 734.7% in SeptemberOctober 11, 2026 | americanbankingnews.comSHTDY - Sinopharm Group Co. Ltd.August 26, 2026 | seekingalpha.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 15 at 1:00 AM | The Oxford Club (Ad)SINOPHARM GRP CO UNSP/ADR by Sinopharm Group Co. Ltd. Stock Short Interest Report | OTC:SHTDY | BenzingaJuly 23, 2026 | benzinga.comSinopharm Group Announces Executive Director ChangesNovember 6, 2025 | msn.comSinopharm Group Schedules Board Meeting to Review Interim ResultsAugust 13, 2025 | msn.comSinopharm Group Co. Ltd. ADR (SHTDY) Stock Price Today - WSJJuly 17, 2025 | wsj.comSinopharm Group Updates Final Dividend Distribution for 2024June 12, 2025 | tipranks.comSee More Headlines SHTDY Stock Analysis - Frequently Asked Questions How have SHTDY shares performed this year? Sinopharm Group's stock was trading at $12.40 at the start of the year. Since then, SHTDY shares have decreased by 20.3% and is now trading at $9.88. How do I buy shares of Sinopharm Group? Shares of SHTDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryN/A Current SymbolOTCMKTS:SHTDY CIK1556605 Webwww.sinopharmgroup.com.cn Phone86-21-2305-2666FaxN/AEmployees94,910Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio1.99 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:SHTDY) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinopharm Group Co. Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinopharm Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
